Moderna Positive Phase 3 Efficacy Data for Next Gen COVID-19 Vaccine

 mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and older

Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older

https://www.accesswire.com/876794/moderna-announces-positive-phase-3-efficacy-data-for-mrna-1283-the-companys-next-generation-covid-19-vaccine